The future of EPAC-targeted therapies: agonism versus antagonism - Wikidata - wikimedia - TriplyDB

The future of EPAC-targeted therapies: agonism versus antagonism

The future of EPAC-targeted therapies: agonism versus antagonism

http://www.wikidata.org/entity/Q34465923

about

Role of EPAC in cAMP-Mediated Actions in Adrenocortical Cells Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.Protein Kinase A Activation Promotes Cancer Cell Resistance to Glucose Starvation and Anoikis The Orphan G Protein-coupled Receptor GPR17 Negatively Regulates Oligodendrocyte Differentiation via Gαi/o and Its Downstream Effector Molecules.Critical role for Epac1 in inflammatory pain controlled by GRK2-mediated phosphorylation of Epac1.A cardiac mitochondrial cAMP signaling pathway regulates calcium accumulation, permeability transition and cell death Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling.Exchange proteins directly activated by cAMP (EPACs): Emerging therapeutic targets.EPAC activation inhibits acetaldehyde-induced activation and proliferation of hepatic stellate cell via Rap1.The role of Epac in the heart.Exchange factors directly activated by cAMP mediate melanocortin 4 receptor-induced gene expression.Epac1 links prostaglandin E2 to β-catenin-dependent transcription during epithelial-to-mesenchymal transition.Epac2-Rap1 Signaling Regulates Reactive Oxygen Species Production and Susceptibility to Cardiac Arrhythmias.A cell-based, quantitative and isoform-specific assay for exchange proteins directly activated by cAMP.The Potential of a Novel Class of EPAC-Selective Agonists to Combat Cardiovascular Inflammation.New Insights in Cardiac Calcium Handling and Excitation-Contraction Coupling.Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.Inhibition of Epac2 Attenuates Neural Cell Apoptosis and Improves Neurological Deficits in a Rat Model of Traumatic Brain Injury.How Rap and its GEFs control liver physiology and cancer development. C3G alterations in human hepatocarcinoma

P2860

Q26744605-BD1204DE-B289-4641-8D4E-05EEC68CCBB0 Q33624262-2E460860-B876-4E5F-B7CE-A385C35AC57E Q35957554-11249DBD-EFCB-460C-8CEA-07ED732880FC Q36442376-162DB5FB-D19D-4E13-99E1-BB3C6EDFFB17 Q36710634-BDADF137-47F9-440A-BFF4-F176E7EDB92C Q36866394-3F4621B4-4F10-44CA-BA12-6AA121628263 Q37708984-7FEF7F3B-00A9-4C92-A257-C30FAB6F1F2A Q38747476-7E014B6E-34D1-49CE-95A8-5A3B2BDFDE47 Q38795720-BCF6736B-9E2B-4A23-8E03-92192C21F51B Q38934306-9EAEA533-4C15-4F86-A1F2-B7C25225BB26 Q39406324-91A7C4AA-C990-4AB0-9D52-10F13CEC1710 Q40854700-C2495A39-56F1-4777-A559-39621FE394DC Q41016215-C782C154-6EFB-40AF-9366-67063983CDDA Q41108182-D0CC9BD2-5C55-4614-AE67-40A6B931968B Q48172039-44D3267C-F321-491C-9BDA-B67BB26D850B Q49689341-A0AC97BA-F6ED-4174-84A4-A2FA6F9DB018 Q52656382-5603955B-DE6F-480D-8576-A0BC478902E2 Q55501040-FFD96BC7-ED66-41F9-A0B6-885403FE856B Q57301410-960FAB1D-9AB6-41EE-B648-C76DD2998934

P2860

The future of EPAC-targeted therapies: agonism versus antagonism

http://www.wikidata.org/entity/Q34465923

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

The future of EPAC-targeted therapies: agonism versus antagonism

@ast

The future of EPAC-targeted therapies: agonism versus antagonism

@en

The future of EPAC-targeted therapies: agonism versus antagonism

@nl

type

label

The future of EPAC-targeted therapies: agonism versus antagonism

@ast

The future of EPAC-targeted therapies: agonism versus antagonism

@en

The future of EPAC-targeted therapies: agonism versus antagonism

@nl

prefLabel

The future of EPAC-targeted therapies: agonism versus antagonism

@ast

The future of EPAC-targeted therapies: agonism versus antagonism

@en

The future of EPAC-targeted therapies: agonism versus antagonism

@nl

P1433

Q34465923-4D43D592-DABC-42AA-8B94-A2D1A451B55B

P1476

Q34465923-53FB16F9-8B30-4A56-8C31-367F207ABE40

P2093

Q34465923-AEE66271-E8AE-42F0-A4E7-284F99C46912

Q34465923-BBDA2F85-81F4-46C4-9930-4C6E85C70188

P275

Q34465923-F02ED707-C746-4C74-8EA4-F5484FC3DC01

P2860

Q34465923-00651111-F43F-48D2-94C1-457C7C7DDBB5

Q34465923-044974D1-9959-45E4-B9A3-DC902261A944

Q34465923-04B08F2E-A680-4443-8F41-B90746A8ABF6

Q34465923-06BB33AF-B5F0-4A71-80AC-85E78D83CC45

Q34465923-070FFE35-04BE-4E98-82CF-9D92C6EFEBB5

Q34465923-0EF98DBD-9A58-4A0D-82B8-1831C5ED9C42

Q34465923-0FB5F200-92DE-4A2C-B9E5-1A1556DFCCD0

Q34465923-13B837C1-CBF3-4C83-B998-D9916A986877

Q34465923-13FE88BF-A809-406E-A71A-F7C470B52D36

Q34465923-151EE564-BCD8-49CE-901B-B42756656E81

P304

Q34465923-7B2B8881-2460-4D77-8C95-CE3A05C29D69

P31

Q34465923-3174F07C-6FBB-47E1-B83E-FDC6C5A2383B

Q34465923-59FB1511-3A1D-47A4-9D46-6301E53109DD

P356

Q34465923-08378F2B-4E0E-48DC-B9AB-9DD659809CCF

P433

Q34465923-AB45CD2A-EEE5-41BF-AD70-8BCB885BCCEB

P478

Q34465923-3DB5B81E-0041-40A3-9BB5-BD67EB1B56EE

P50

Q34465923-1CCF65C9-5C3F-4E0B-9B66-5FDCC42B748C

P577

Q34465923-861E5FD8-6108-4A21-9AB3-C54E38FBFF8F

Q34465923-C03D96CF-12E0-4970-9081-E55A0928B956

P5875

Q34465923-D1C0795F-0EAF-4B7B-BE2B-8DDEC733C86B

P698

Q34465923-ADBEE179-82BB-4097-B9CA-16BBD8AFC4F9

P921

Q34465923-414251A3-71DB-416F-BA23-52A3F73EEA4B

P932

Q34465923-078E5406-CE74-4278-A92A-D2E235EE2D08

P356

J.TIPS.2015.02.003

P1433

Trends in Pharmacological Sciences

P1476

The future of EPAC-targeted therapies: agonism versus antagonism

@en

P2093

Euan Parnell

http://www.w3.org/2001/XMLSchema#string

Timothy M Palmer

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP

A family of cAMP-binding proteins that directly activate Rap1

Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs

The RAP1 guanine nucleotide exchange factor Epac2 couples cyclic AMP and Ras signals at the plasma membrane

Structure of Epac2 in complex with a cyclic AMP analogue and RAP1B

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell

The cAMP-binding Popdc proteins have a redundant function in the heart

Regulatory subunit of protein kinase A: structure of deletion mutant with cAMP binding domains

Epac-selective cAMP analog 8-pCPT-2'-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic beta-cells.

P304

203-214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TIPS.2015.02.003

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Stephen J. Yarwood

P577

2015-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273154703

http://www.w3.org/2001/XMLSchema#string

P698

25744542

http://www.w3.org/2001/XMLSchema#string

P921

P932

4392396

http://www.w3.org/2001/XMLSchema#string